Shares of Eli Lilly and Co. (LLY) were barely moving in Monday's premarket session. That's the kind of quiet you sometimes get when a big pharmaceutical company announces clinical trial data that is, well, exactly what everyone hoped it would be.

The drug giant shared results from a Phase 3 trial for its cancer drug Jaypirca (pirtobrutinib). The study, called BRUIN CLL-322, tested Jaypirca in combination with two other drugs—venetoclax and rituximab—in patients with a type of blood cancer called relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). For the record, CLL/SLL is a cancer of a white blood cell called the B-lymphocyte. One of the combo drugs, venetoclax, is sold by AbbVie Inc. (ABBV) under the brand name Venclexta.

The key takeaway? Adding Jaypirca led to a statistically significant improvement in progression-free survival. That's the important metric for showing a treatment is working to keep the cancer from getting worse. Overall survival data, another critical endpoint, wasn't mature yet at this analysis but was, as they say in the biz, "trending in favor" of the Jaypirca combo. The detailed results will be presented at a medical meeting and submitted for publication, and Eli Lilly plans to take this data to regulators later this year to ask for an expanded label for the drug.

Here's why this matters beyond just one trial: this is now the fourth positive Phase 3 study for pirtobrutinib. In drug development, that's like building a very strong legal case. You don't just have one witness; you have multiple lines of evidence all pointing in the same direction. It significantly bolsters the argument for expanding where and how the drug can be used.

The company's case gets even stronger when you look at how Jaypirca stacks up against the competition. Data from another Phase 3 trial, BRUIN CLL-314, pitted Jaypirca head-to-head against Johnson & Johnson's blockbuster drug Imbruvica (ibrutinib). Jaypirca met the primary endpoint, showing it was non-inferior to Imbruvica on overall response rate (87.0% for Jaypirca vs. 78.5% for Imbruvica). It also had numerically higher response rates. While the progression-free survival data is still immature, it was also trending favorably for Jaypirca, including showing a 76% reduction in the risk of disease progression or death in a subgroup of previously untreated patients.

And if beating the market leader isn't enough, Jaypirca also beat the older standard of care. A third Phase 3 trial (BRUIN CLL-313) showed Jaypirca provided a "highly statistically significant and clinically meaningful" improvement in progression-free survival compared to chemoimmunotherapy.

While the spotlight is on Jaypirca today, Eli Lilly is also building momentum in another cancer area. Back in February, the company shared positive top-line results from a Phase 3 trial for its lung cancer drug Retevmo (selpercatinib). The LIBRETTO-432 trial showed the drug delivered a significant improvement in event-free survival for patients with early-stage non-small cell lung cancer, substantially reducing the risk of the disease coming back or causing death.

So, what did the market think of all this promising news on a Monday morning? According to market data, Eli Lilly shares were down a microscopic 0.01% at $939.36 in premarket trading. Sometimes, when you deliver exactly what's expected, the reaction is a calm nod rather than a standing ovation. For Eli Lilly, the real payoff will come if regulators give the nod to these expanded uses later this year.